Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

References

• Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168(4):421–5. PMID:12591782.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9. doi:10.1016/S1473-3099(07)70158-5. PMID:17597569.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9. doi:10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH431%3e3.0.CO;2-F. PMID:10451482.
   PubMed Web of Science ®Google Scholar
• International Agency for the Research of Cancer. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in. 2012.
   Google Scholar
• Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009;40(6):478–85. doi:10.1016/j.arcmed.2009.06.003. PMID:19853188.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Gardasil 9. summary of product characteristics. 2015.
   Google Scholar
• Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33(48):6855–64. doi:10.1016/j.vaccine.2015.08.059. PMID:26411885.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044. PMID:25693011.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–2159. doi:10.1016/S0140-6736(17)31821-4. PMID:28886907.
   PubMed Web of Science ®Google Scholar
• Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000;36(17):2209–14. doi:10.1016/S0959-8049(00)00311-7. PMID:11072206.
   PubMed Web of Science ®Google Scholar
• Bigaard J, Hariri J, Lynge E. Cervical cancer screening in Denmark. Eur J Cancer. 2000;36(17):2198–204. doi:10.1016/S0959-8049(00)00309-9. PMID:11072204.
   PubMed Web of Science ®Google Scholar
• Dillner J. Cervical cancer screening in Sweden. Eur J Cancer. 2000;36(17):2255–9. doi:10.1016/S0959-8049(00)00320-8. PMID:11072216.
   PubMed Web of Science ®Google Scholar
• Perez-Gomez B, Martinez C, Navarro C, Franch P, Galceran J, Marcos-Gragera R. The moderate decrease in invasive cervical cancer incidence rates in Spain (1980–2004): limited success of opportunistic screening? Ann Oncol. 2010;21(Suppl 3):iii61–68. PMID:20427362.
   PubMed Web of Science ®Google Scholar
• Adab P, McGhee SM, Yanova J, Wong CM, Hedley AJ. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Med Care. 2004;42(6):600–9. doi:10.1097/01.mlr.0000128007.04494.29. PMID:15167328.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, et al. Eurogin Roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programmes. Int J Cancer. 2018. doi:10.1002/ijc.31261. PMID:29341110. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Brisson M, Benard E, Drolet M, Bogaards JA, Baussano I, Vanska S, Jit M, Boily MC, Smith MA, Berkhof J, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–e17. doi:10.1016/S2468-2667(16)30001-9. PMID:29253379.
   PubMed Web of Science ®Google Scholar
• Mendes D, Bains I, Vanni T, Jit M. Systematic review of model-based cervical screening evaluations. BMC Cancer. 2015;15:334. doi:10.1186/s12885-015-1332-8. PMID:25924871.
   PubMed Web of Science ®Google Scholar
• Kjaer K, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-Year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clinical Infectious Diseases. 2018;66(3):339–345
   PubMed Web of Science ®Google Scholar
• Thomas GM. Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340(15):1198–200. doi:10.1056/NEJM199904153401509. PMID:10202172.
   PubMed Web of Science ®Google Scholar
• Dillner J. Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol. 2000;19(1–2):7–23. doi:10.1016/S1386-6532(00)00126-8. PMID:11091144.
   PubMed Web of Science ®Google Scholar
• Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364(9430):249–56. doi:10.1016/S0140-6736(04)16674-9. PMID:15262102.
   PubMed Web of Science ®Google Scholar
• Paling J. Strategies to help patients understand risks. BMJ. 2003;327(7417):745–8. doi:10.1136/bmj.327.7417.745. PMID:14512489.
   PubMed Web of Science ®Google Scholar
• Day NE. Cancer Incidence in Five Continents. Cumulative rate and cumulative risk. IARC Sci Publ. 1992;(120):862–4.
   Google Scholar
• R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria; 2013.
   Google Scholar
• Trent Cancer Registry. http://www.empho.org.uk/tcr/aboutUs.aspx, Last accessed: November 27, 2015.
   Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi:10.1016/S1470-2045(10)70230-8. PMID:20952254.
   PubMed Web of Science ®Google Scholar
• Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol. 2014;180(5):545–55. doi:10.1093/aje/kwu159. PMID:25081182.
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672–82. doi:10.1016/S1470-2045(09)70156-1. PMID:19540162.
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72. doi:10.1016/S0140-6736(07)61450-0. PMID:17919718.
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97. doi:10.1056/NEJMoa073204. PMID:17942872.
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57. doi:10.1016/S1470-2045(09)70360-2. PMID:20089449.
   PubMed Web of Science ®Google Scholar
• McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–34. doi:10.1016/S1470-2045(08)70103-7. PMID:18407790.
   PubMed Web of Science ®Google Scholar
• Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111(5):965–9. doi:10.1038/bjc.2014.362. PMID:24992581.
   PubMed Web of Science ®Google Scholar
• NORDCAN. http://www-dep.iarc.fr/nordcan.htm, Last accessed: November 27, 2015.
   Google Scholar